Janghwan Park, Honorary Professor at Hanyang University, Appointed as Director of Pan-Government Regenerative Medicine Technology Development Project

"Accumulated Research Achievements Will Be Swiftly Connected to Clinical Application and Commercialization"

The Ministry of Health and Welfare and the Ministry of Science and ICT announced on April 16 that they have appointed Janghwan Park, research project management expert at the Korea Health Industry Development Institute and honorary professor at Hanyang University, as the 2nd Project Director of the Pan-Government Regenerative Medicine Technology Development Project.

Janghwan Park, Second Project Director of the Pan-Government Regenerative Medicine Technology Development Project. Ministry of Health and Welfare

The Pan-Government Regenerative Medicine Technology Development Project aims to secure core and fundamental technologies in the field of regenerative medicine, supporting the entire development cycle of stem cell and gene-based therapeutics and treatment technologies. It brings together the capabilities of industry, academia, research institutes, and hospitals to develop world-class regenerative medicine therapeutics, generate patents, and promote technology transfer achievements. This large-scale national research and development project is jointly operated by the Ministry of Health and Welfare and the Ministry of Science and ICT, with a total budget of 595.5 billion won (542.3 billion won in government funding and 53.2 billion won from the private sector) to be invested over ten years from 2021 to 2030.

The project director has comprehensive responsibility for the operation of the project group, including planning, evaluation, and management of the project, as well as the utilization and dissemination of research outcomes and support for commercialization. In January of this year, a public recruitment was held. After document and presentation evaluations, the final candidate was confirmed through deliberation and resolution by the board of directors.

The newly appointed Project Director Park is recognized as an expert equipped with broad experience and organizational management capabilities across the entire cycle of basic research, clinical studies, and commercialization in the field of regenerative medicine, having previously served as Director of New Drug Projects at the National Research Foundation of Korea and as a research project management expert at the Korea Health Industry Development Institute. The term of office is three years, which may be extended by an additional two years upon evaluation.

Director Park stated, "I will swiftly connect the accumulated research achievements in the regenerative medicine field to clinical application and commercialization, leading to tangible results," adding, "I will do my utmost to generate outcomes that the public can feel and strengthen global competitiveness in the field of regenerative medicine."

This content was produced with the assistance of AI translation services.